^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    BluePrint

    Company:
    Agendia
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Sensitive: B - Late Trials

    [HER-2 positive-HER2 Positive Breast Cancer-trastuzumab + pertuzumab]

    Source:
    SABCS 2020
    Test:

    BluePrint

    Title:
    BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial
    Published date:
    11/17/2020
    Excerpt:
    We hypothesized that BluePrint could identify a subgroup of patients within the APHINITY population who derived additional benefit from the addition of P to C/T....In this exploratory analysis, HER2+ tumors with a single transcriptional HER2 activated pathway showed a trend for greater benefit from pertuzumab than tumors in which multiple mitogenic pathways are activated.
    Secondary therapy:
    Chemotherapy
    Trial ID:
    APHINITY